Blog

CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma – Markets Insider


Medical Xpress

CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma
Markets Insider
ATLANTA, Dec. 10, 2017 /PRNewswire-USNewswire/ — For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH
Landmark CART cancer study publishedMedical Xpress



all 5 news articles »

2017-12-10 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.